142 related articles for article (PubMed ID: 32007387)
1. Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
Kuramoto K; Yamada H; Shin T; Sawada Y; Azami H; Yamada T; Nagashima T; Ohnuki K
Bioorg Med Chem; 2020 Mar; 28(5):115307. PubMed ID: 32007387
[TBL] [Abstract][Full Text] [Related]
2. Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity.
Kuramoto K; Sawada Y; Yamada T; Nagashima T; Ohnuki K; Shin T
Chem Pharm Bull (Tokyo); 2020; 68(5):452-465. PubMed ID: 32378543
[TBL] [Abstract][Full Text] [Related]
3. AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth.
Xia YC; Zha JH; Sang YH; Yin H; Xu GQ; Zhen J; Zhang Y; Yu BT
Cell Death Dis; 2021 Apr; 12(4):365. PubMed ID: 33824293
[TBL] [Abstract][Full Text] [Related]
4. Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators.
Dokla EM; Fang CS; Lai PT; Kulp SK; Serya RA; Ismail NS; Abouzid KA; Chen CS
ChemMedChem; 2015 Nov; 10(11):1915-23. PubMed ID: 26350292
[TBL] [Abstract][Full Text] [Related]
5. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 3,5-Dimethylpyridin-4(1H)-one Derivatives as Activators of AMP-Activated Protein Kinase (AMPK).
Kuramoto K; Sawada Y; Ishibashi N; Yamada T; Nagashima T; Shin T
Chem Pharm Bull (Tokyo); 2020; 68(1):77-90. PubMed ID: 31902903
[TBL] [Abstract][Full Text] [Related]
7. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Velaparthi U; Wittman M; Liu P; Carboni JM; Lee FY; Attar R; Balimane P; Clarke W; Sinz MW; Hurlburt W; Patel K; Discenza L; Kim S; Gottardis M; Greer A; Li A; Saulnier M; Yang Z; Zimmermann K; Trainor G; Vyas D
J Med Chem; 2008 Oct; 51(19):5897-900. PubMed ID: 18763755
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.
Yan G; Pu C; Lan S; Zhong X; Zhou M; Hou X; Yang J; Shan H; Zhao L; Li R
Eur J Med Chem; 2019 Sep; 178():667-686. PubMed ID: 31228810
[TBL] [Abstract][Full Text] [Related]
9. Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.
Lin SY; Chang CF; Coumar MS; Chen PY; Kuo FM; Chen CH; Li MC; Lin WH; Kuo PC; Wang SY; Li AS; Lin CY; Yang CM; Yeh TK; Song JS; Hsu JTA; Hsieh HP
Bioorg Chem; 2020 May; 98():103689. PubMed ID: 32171993
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
11. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
12. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.
Matheson CJ; Casalvieri KA; Backos DS; Minhajuddin M; Jordan CT; Reigan P
Eur J Med Chem; 2020 Jul; 197():112316. PubMed ID: 32334266
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.
Wu Y; Sarkissyan M; Mcghee E; Lee S; Vadgama JV
Breast Cancer Res Treat; 2015 Jun; 151(3):529-39. PubMed ID: 25975952
[TBL] [Abstract][Full Text] [Related]
14. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
15. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile.
Jin T; Xu L; Wang P; Hu X; Zhang R; Wu Z; Du W; Kan W; Li K; Wang C; Zhou Y; Li J; Liu T
J Med Chem; 2021 Oct; 64(20):15069-15090. PubMed ID: 34665631
[TBL] [Abstract][Full Text] [Related]
18. Involvement of AMP-activated protein kinase and p38 mitogen-activated protein kinase in 8-Cl-cAMP-induced growth inhibition.
Han JH; Ahn YH; Choi KY; Hong SH
J Cell Physiol; 2009 Jan; 218(1):104-12. PubMed ID: 18756496
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Myers SM; Miller DC; Molyneux L; Arasta M; Bawn RH; Blackburn TJ; Cook SJ; Edwards N; Endicott JA; Golding BT; Griffin RJ; Hammonds T; Hardcastle IR; Harnor SJ; Heptinstall AB; Lochhead PA; Martin MP; Martin NC; Newell DR; Owen PJ; Pang LC; Reuillon T; Rigoreau LJM; Thomas HD; Tucker JA; Wang LZ; Wong AC; Noble MEM; Wedge SR; Cano C
Eur J Med Chem; 2019 Sep; 178():530-543. PubMed ID: 31212132
[TBL] [Abstract][Full Text] [Related]
20. Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer.
Yang H; Wang X; Wang C; Yin F; Qu L; Shi C; Zhao J; Li S; Ji L; Peng W; Luo H; Cheng M; Kong L
Eur J Med Chem; 2021 Jan; 210():113080. PubMed ID: 33310286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]